Edgewise Board Member Gets $440K Stock Option Package with One-Year Vest

Rhea-AI Filing Summary

Edgewise Therapeutics (EWTX) director Badreddin Edris received a stock option grant for 30,000 shares of common stock on June 16, 2025. The options were granted with an exercise price of $14.68 per share.

Key terms of the stock option grant:

• Exercise price: $14.68 per share
• Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
• Expiration date: June 16, 2035
• Ownership form: Direct

The Form 4 was filed by attorney-in-fact John R. Moore on behalf of Badreddin Edris on June 18, 2025, within the required two-business-day filing window following the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Edris Badreddin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edris Badreddin

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.68	06/16/2025		A		30,000		06/16/2026(1)	06/16/2035	Common Stock	30,000	$0.00	30,000	D

Explanation of Responses:

1. 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.

Remarks:

	/s/John R. Moore Attorney-in-Fact for Badreddin Edris	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did EWTX director Badreddin Edris receive on June 16, 2025?

According to the Form 4 filing, EWTX director Badreddin Edris received 30,000 stock options (Right to Buy) on June 16, 2025, with an exercise price of $14.68 per share.

What is the vesting schedule for EWTX director Edris's June 2025 stock options?

The stock options will become 100% vested on the earlier of: (i) June 16, 2026, or (ii) the business day prior to the 2026 annual meeting of stockholders.

What is the expiration date for EWTX director Edris's stock options granted in June 2025?

The stock options granted to director Badreddin Edris have an expiration date of June 16, 2035, giving them a 10-year term from the grant date.

What is the exercise price of EWTX stock options granted to director Edris in June 2025?

The stock options were granted with an exercise price of $14.68 per share.

Who signed the Form 4 filing for EWTX director Badreddin Edris?

The Form 4 was signed by John R. Moore as Attorney-in-Fact for Badreddin Edris on June 18, 2025.